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Abstract
The dorsal striatum plays an important role in the development of drug addiction; however, a 
precise understanding of the roles of striatopallidal (indirect) and striatonigral (direct) pathway 
neurons in regulating behaviors remains elusive. Using a novel approach that relies on the viral-
mediated expression of an engineered GPCR (hM4D), we demonstrated that activation of hM4D 
receptors with clozapine-N-oxide (CNO) potently reduced striatal neuron excitability. When 
hM4D receptors were selectively expressed in either direct or indirect pathway neurons in rats, 
CNO did not change acute locomotor responses to amphetamine but altered behavioral plasticity 
associated with repeated drug treatment. Specifically, transiently disrupting striatopallidal 
neuronal activity facilitated behavioral sensitization whereas decreasing excitability of 
striatonigral neurons impaired its persistence. These findings suggest that acute drug effects can be 
parsed from the behavioral adaptations associated with repeated drug exposure and highlight the 
utility of this approach for deconstructing neuronal pathway contributions to behaviors such as 
sensitization.
Despite the overwhelming negative consequences of drug addiction, psychostimulant usage 
and abuse remains prevalent. The progression from initial drug exposure to regular use and 
ultimately to compulsive, habitual behavior and the loss of inhibitory control involves a 
series of molecular adaptations in discrete neurocircuits1,2,3. The striatum has been 
identified as a key site for many of the behavioral and neurobiological adaptations thought 
to form the core processes that mediate addiction1,2,3. The majority of neurons within the 
striatum (~95%) are GABAergic medium spiny projection neurons (MSNs) that differ in 
their neuropeptide expression and form two major efferent pathways4. Striatopallidal MSNs 
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contain enkephalin (ENK) and form the indirect pathway whereas striatonigral MSNs 
contain dynorphin (DYN) and substance P and form the direct pathway. Many conceptual 
models hypothesize that these populations of MSNs oppose one another both 
mechanistically and functionally5,6. However, there is little empirical evidence to support 
their differential role in the control of behavior because these cell populations are physically 
intermingled and morphologically indistinguishable making selective manipulation 
technically elusive.
To examine the role of these striatal cell populations in the development of behaviors that 
occur following repeated exposure to drugs of abuse, we combined two novel strategies: 
viral vectors that use either the ENK or DYN gene promoters to target transgene expression 
to striatopallidal or striatonigral neurons, respectively, and an engineered GPCR (Gi/o-
coupled human muscarinic M4 DREADD; Designer Receptor Exclusively Activated by a 
Designer Drug; hM4D)7 that is activated by an otherwise pharmacologically inert ligand, 
clozapine-N-oxide8,9 (CNO; Fig. 1a, h). Following expression in cultured neurons, 
administration of CNO stimulates Gi/o-coupled hM4D receptors thus activating inwardly 
rectifying potassium 3 (Kir3) channels, resulting in membrane hyperpolarization and 
transient neuronal silencing9.
To test for cell phenotype specificity of the viral vectors, we used dual-label 
immunofluorescence microscopy following dorsal striatum infusion of viruses 
(Supplementary Fig. 1) that express hemagglutinin-tagged hM4D receptors under the control 
of either the ENK promoter (pENK-hM4D) or the DYN promoter (pDYN-hM4D). We found 
that pENK-hM4D expression was primarily in ENK-containing MSNs (90% of 
hemagglutinin cells were ENK+, 85 out of 94; 6% of hemagglutinin cells were substance P
+, 4 out of 70 cells; Fig. 1b) whereas pDYN-hM4D expression was primarily in substance P-
containing MSNs (95% of hemagglutinin cells were substance P+, 109 out of 115 cells; 5% 
of hemagglutinin cells were ENK+, 5 out of 97 cells; Fig. 1i). Similar results were obtained 
following infusion of promoter-specific viruses that express green fluorescent protein 
(pENK-GFP and pDYN-GFP; SupplementaryFigs. 2a and 3a).
Given that striatopallidal MSNs primarily project to the globus pallidus external (GPe) and 
striatonigral MSNs primarily project to the substantia nigra pars reticulata (SNpr), we used 
injections of the retrograde tracer Fluoro-Gold into these brain regions followed by dual-
label fluorescent immunohistochemistry to confirm that the pENK and pDYN viruses yielded 
pathway-specific infection. We observed that pENK-GFP cells co-localized with striatal 
Fluoro-Gold expression following infusions into the GPe but not the SNpr (Supplementary 
Fig. 2b) whereas pDYN-GFP cells co-localized with striatal Fluoro-Gold expression 
following infusions into the SNpr but not the GPe (Supplementary Fig. 3b). Expression of 
the viral vectors did not change the number of ENK+ or substance P+ neurons in the region 
of viral infection, suggesting that use of these promoters for viral-mediated gene transfer did 
not interfere with endogenous neuropeptide levels. All of these results demonstrate that the 
pENK and pDYN viral vectors express genes in their appropriately segregated striatal cell 
populations.
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Although hM4D receptor-based techniques have been demonstrated to modulate activity of 
other neuronal types9, their ability to affect striatal neurons has not been examined. 
Therefore, we infected striatal medium spiny neurons with hM4D receptors under the control 
of a herpes simplex virus (HSV) promoter, prepared coronal slices of dorsal striatum two 
days later, and examined how hM4D-expressing medium spiny striatal neurons respond to 
CNO. We observed that local application of CNO (10 μM) induced a hyperpolarization of 
the membrane potential (~7 mV, the baseline membrane potential was adjusted to −80 mV; 
Fig. 1c) and reduced the input resistance of the neurons after CNO application (Fig. 1d, e), 
suggesting that potassium conductance (i.e., Kir3-mediated current) is activated by CNO in 
hM4D receptor-expressing neurons. Furthermore, perfusion of CNO substantially decreased 
the number of evoked action potentials in hM4D-expressing neurons, but not in control cells, 
thereby effectively inhibiting the functional output of the virally-infected neurons 
Expression of hM4D receptors alone did not alter input resistance (P = 0.84) or action 
potential firing (P = 0.64). (Fig. 1f, g). Taken together, these data suggest that, similar to 
hippocampal neurons9, the hM4D/CNO-based method can effectively decrease the 
excitability of rat striatal neurons.
As additional proof of concept, we tested whether hM4D receptors would block 
neurotransmission in a well-established circuit where neural activity is predictably evoked 
by behaviorally-relevant stimuli. Accordingly, we infected ventral tegmental area (VTA) 
neurons with hM4D receptors under control of a HSV promoter, which expresses strongly in 
dopamine neurons10, and used fast-scan cyclic voltammetry to measure changes in 
dopamine release in the nucleus accumbens after unexpected delivery of a food reward11. 
Administration of CNO significantly attenuated food pellet-evoked dopamine release in the 
nucleus accumbens compared to vehicle (Supplementary Fig. 4). Finally, we tested whether 
decreasing activity of specific neuronal cell types in the striatum in vivo could alter the 
ability of amphetamine to stimulate Fos expression. Psychostimulants, such as 
amphetamine, are robust activators of c-fos in the striatum12 and will increase c-fos in both 
striatonigral and striatopallidal neurons under our experimental conditions13. In addition to 
its use as a marker of neuronal activity, psychostimulant induction of c-fos is thought to play 
an important role in the initiation and maintenance of the neural adaptations associated with 
psychomotor sensitization1,14. We found that CNO-mediated activation of pENK-hM4D 
receptors significantly reduced the total number of amphetamine-induced c-Fos cells in the 
striatum (Fig. 1k and Supplementary Fig. 5a). This reduction occurred in both 
hemagglutinin-positive neurons (i.e, those expressing hM4D receptors) and hemagglutinin-
negative neurons (i.e., those not expressing hM4D receptors; Fig. 1l), suggesting a neuronal 
cross-talk effect between hM4D-expressing neurons and uninfected neurons. Significant 
reductions in the total number of amphetamine-evoked c-Fos cells and in the number of 
hemagglutinin-positive c-Fos cells were also seen when hM4D receptors were activated in 
direct pathway neurons (Fig. 1n, o and Supplementary Fig. 5b). Importantly, these effects 
are not simply caused by viral expression of a novel receptor since expression of either 
pENK-hM4D or pDYN-hM4D receptors in the absence of CNO treatment had no effect on 
the number of amphetamine-evoked Fos cells (Supplementary Figs. 6 and 7). Thus, these 
findings demonstrate that the CNO-mediated activation of hM4D receptors can also lead to 
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decreases in neuronal activity by reducing neurotransmitter release and attenuating 
intracellular signaling.
Repeated exposure to addictive drugs can lead to a progressive and persistent increase in 
behavioral responsiveness, often referred to as behavioral sensitization. Importantly, 
sensitization involves some of the same neural circuits implicated in the development of 
human drug addiction3. Here we use our novel tools to investigate the effect of circuit-
specific dampening of striatal neuron activity on the development of amphetamine 
sensitization. We hypothesized that direct and indirect pathway neurons have opposing roles 
where striatonigral neurons promote sensitization and striatopallidal neurons suppress 
sensitization, consistent with their conceptually-proposed roles in behavioral activation and 
inhibition respectively5,6. Accordingly, we tested whether biochemically decreasing 
neuronal excitability of striatopallidal neurons would induce sensitization to an 
amphetamine-dosing regimen that elicits a threshold level of sensitization and whether 
decreasing neuronal excitability of striatonigral neurons would prevent sensitization in a 
protocol that normally produces robust sensitization.
For the first study, we used a treatment regimen that induces a threshold level of locomotor 
sensitization in GFP controls (four drug exposures). Following a withdrawal period, a 
moderate challenge amphetamine dose (2 mg/kg) was administered in the absence of CNO-
induced attenuation of neuronal activity to determine if sensitization was persistent. CNO-
mediated activation of pENK-hM4D receptors during amphetamine treatment did not alter 
the acute locomotor response to amphetamine (Fig. 2a). However, CNO-mediated disruption 
of neuronal activity in indirect-pathway neurons facilitated the development of a 
significantly more robust sensitization compared to GFP controls (Fig. 2b). This 
enhancement of sensitization was maintained on the amphetamine challenge, which was 
conducted one-week later in the absence of CNO treatment (Fig. 2c, d). These effects can be 
attributed to a CNO-dependent reduction of activity of striatopallidal neurons by hM4D 
receptors because hM4D receptor expression without CNO treatment does not produce 
locomotor sensitization to this mild dosing regimen of amphetamine (Supplementary Fig. 6).
In order to determine whether striatonigral neurons can regulate drug responsiveness in an 
opposing fashion, we next tested the effect of biochemically diminishing excitability of 
striatonigral neurons in the dorsomedial striatum during a drug treatment regimen of 
amphetamine that produces robust sensitization in GFP controls (six drug exposures) as well 
as during a low challenge dose of amphetamine (0.5 mg/kg) in the absence of receptor-
mediated disruption of neuronal activity. As with indirect pathway dampening, CNO-
mediated decreases of excitability of direct pathway neurons during amphetamine treatment 
did not alter the acute locomotor response to amphetamine (Fig. 2e). Although the 
development of sensitization appeared similar to the GFP controls following CNO-induced 
activation of pDYN-hM4D receptors during the treatment phase (Fig. 2f), sensitization did 
not persist in the pDYN-hM4D group but was still robustly maintained in the GFP controls 
(Fig. 2g, h). These effects can also be attributed to a CNO-dependent decrease of activity of 
striatonigral neurons by hM4D receptors because hM4D receptor expression in the absence 
of CNO treatment did not block the development of locomotor sensitization as sensitization 
was observed during the treatment phase and on the drug challenge (Supplementary Fig. 7). 
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These data suggest that striatonigral neurons may be particularly important for regulating the 
long-term behavioral adaptations that are a consequence of repeated drug use.
In conclusion, these data provide the first evidence for the critical, and opposing, roles of 
striatopallidal and striatonigral neurons in the regulation of drug experience-dependent 
behavior plasticity. In addition, the lack of effect of neuronal inhibition on the acute 
locomotor response to amphetamine provides further evidence that the mechanisms that 
regulate acute responses to drugs are distinct from those that modulate the enduring 
adaptations that occur with repeated drug exposure. Finally, pairing phenotypic-specific 
viral vectors with designer receptors capable of altering neuronal activity without 
permanently disrupting cell function provides a novel and powerful approach for 
deconstructing the molecular basis of addiction.
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Transient and targeted attenuation of striatal cell signaling. (a, h) Amplicon maps of pENK-
hM4D/pENK-GFP (a) and pDYN-hM4D/pDYN-GFP (h) targeting vectors. (b, i) Confocal 
microscopy showed that pENK-hM4D receptors were selectively expressed in striatopallidal 
MSNs (b) whereas pDYN-hM4D receptors were selectively expressed in striatonigral MSNs 
(i). Green, hemagglutinin (HA); Red, ENK (top) and substance P (SP, bottom); Yellow, co-
localization of neurons. Scale bars, 10 μm. (c) Representative voltage trace of CNO-induced 
hyperpolarization of an hM4D-expressing striatal neuron. (d, e) CNO decreased input 
resistance in hM4D-expressing neurons. * P < 0.05 hM4D before vs. hM4D after CNO 
application, n=4–5. (f, g) Representative traces (f) and summarized data (g) showed that 
CNO decreased the number of evoked action potentials in hM4D-expressing neurons. ** P < 
0.01 hM4D vs. hM4D/CNO (k, n) CNO-mediated activation of pENK-hM4D (k) or pDYN-
hM4D (n) receptors decreased the number of amphetamine-induced Fos cells (CON: 
vehicle-treated pENK-hM4D and pDYN-hM4D, respectively) (pENK: P = 0.002, n=5–6/
group; pDYN: P < 0.05, n=5–6/group). (l, o) Amphetamine-evoked c-Fos+ cells were 
reduced in both hemagglutinin-positive (P < 0.05) and hemagglutinin-negative (P < 0.01) 
neurons in the pENK-hM4D experiment (l) and in hemagglutinin-positive neurons (P < 
0.05) in the pDYN-hM4D experiment (o). Representative Fos immunohistochemistry 
sections (red) from pENK-hM4D (j) and pDYN-hM4D (m) infused striatum of vehicle (VEH) 
and CNO-treated rats. Scale bars, 50 μm. Insets depict single-labeled Fos cells (red), 
hemagglutinin cells (green) and dual-labeled cells (yellow). Scale bars, 10 μm. Data 
represent mean ± SEM. V = vehicle treatment, C = CNO treatment.
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Transiently reducing excitability of striatopallidal or striatonigral neurons had opposing 
effects on amphetamine sensitization. (a, e) Acute locomotor responses to amphetamine 
following CNO-induced activation of pENK-hM4D (a) and pDYN-hM4D (e) receptors. 
pENK, n = 9–10/group; pDYN, n = 8–10/group, ***P < 0.001 versus saline-treated groups. 
(b) Activation of pENK-hM4D receptors during amphetamine treatmentenhanced the 
development of locomotor sensitization. ***P < 0.001 versus Session 1, ###P < 0.001 
versus amphetamine-treated GFP group). (c, d) Enhanced sensitization in the amphetamine-
pretreated pENK-hM4D group was maintained during the challenge test. ***P < 0.001 
versus saline-pretreated group, ##P < 0.01 versus amphetamine-pretreated GFP group. (f) 
Activation of pDYN-hM4D receptors during amphetamine treatment initially produced 
locomotor sensitization similar to pDYN-GFP controls. **P < 0.01 and *P < 0.05 versus 
Session 1. (g, h) Sensitization in the amphetamine-pretreated pDYN-hM4D group was no 
longer evident on the challenge test. ***P < 0.001 versus saline-pretreated groups, #P < 
0.05 versus amphetamine-pretreated GFP group. Data represent mean ± SEM. S = saline, A 
= amphetamine. Squares represent hM4D groups, circles represent GFP groups. Light grey 
and black symbols represent rats that received amphetamine during the treatment phase, 
white and dark grey symbols represent rats that received saline during the treatment phase. 
All experimental procedures were approved by the University of Washington Institutional 
Animal Care and Use Committee and were conducted in accordance with National Institutes 
of Health guidelines. See supplementary methods for additional statistics information.
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